A growing body of evidence suggests that popular GLP-1 drugs, widely used for weight loss and diabetes, can provide ...
Stephen has degrees in science (Physics major) and arts (English Literature and the History and Philosophy of Science), as well as a Graduate Diploma in Science Communication. Stephen has degrees in ...
HealthDay on MSN
ASCO: GLP-1 receptor agonist initiation cuts metastatic progression across cancer types
Across multiple solid tumors, glucagon-like peptide 1 receptor agonist (GLP-1 RA) initiation after cancer diagnosis is ...
Real-world data show that GLP-1 receptor agonists (GLP-1s) may reduce metastatic progression of certain obesity-related cancers, namely lung, breast, colorectal, and liver cancers. In addition, GLP-1 ...
Patients who discontinued tirzepatide during the 17-week off-treatment period began to regain weight. Tirzepatide significantly reduced the risk of progression to type 2 diabetes in adults with ...
A trial comparing baricitinib against placebo in people with new-onset type 1 diabetes suggests use could contribute to the preservation of β-cell function. Baricitinib (Olumiant), an agent used in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results